Indefinite Delivery Contract 75D30122D14071
Award Date
7/1/22
Last Date to Order
6/30/23
Federal Agency
CDC Pittsburgh
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts hold a potential value of $102.6 million and require the awarded vendors to provide 13 vaccines to support immunization programs administered by state and local health authorities pursuant to Section 317(j) of the Public Health Service Act. Vaccines include hepatitis A and B, pneumococcal, tetanus/diphtheria, herpes...
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for 2019 adult vaccines. The multiple award IDC has a potential value of $1,602,700 and a period of performance from July 1, 2019 through June 30, 2020. Grifols will supply various adult vaccines to support public health programs through the CDC. As a manufacturer of pharmaceuticals and medical products, Grifols has extensive experience providing specialized drugs, vaccines, immunoglobulins and...
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for adult vaccines with a potential value of $1,626,900. No set-aside provisions were applied. Under this contract, Grifols will supply various adult vaccines to the CDC on an as-needed basis through task orders issued between July 1, 2020 and June 30, 2021. As a manufacturer and distributor of pharmaceuticals and medical products, Grifols maintains several schedule contracts and indefinite...
The federal contract IDV award is for the supply of various adult vaccines to the Centers for Disease Control and Prevention (CDC) for the period of July 1, 2023 through June 30, 2024. The contract was awarded to Grifols USA LLC, a global healthcare company specializing in the manufacturing and distribution of plasma-derived medicines and pharmaceutical supplies. The contract has a ceiling value of $1,842,400.00 and includes the supply of 12 different adult vaccines, including hepatitis,...
This federal contract indefinite delivery vehicle (IDV) was awarded to Grifols USA LLC by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to provide a variety of adult vaccines. The contract has a potential value of $1,647,100 and a period of performance from July 1, 2021 to June 30, 2022. The vaccines to be supplied under this IDV include hepatitis, pneumococcal, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal, human...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts to Pfizer Inc. for the delivery of various adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $62.2 million. Through these contracts, Pfizer will provide 12 standard adult vaccines to the CDC including hepatitis A & B, pneumococcal, tetanus/diphtheria, herpes zoster, Tdap, MMR, meningococcal,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Grifols USA LLC to supply 20 standard pediatric vaccines in support of the Vaccines for Children program. The contract utilizes multiple awards with a potential value of $12.2 million and period of performance through March 2022. Vaccines will be ordered via task orders against flexible delivery schedules to meet quantities ranging from a minimum of 100 doses to a maximum of 13 million doses per item. The...